Table 1 Characteristics of patients in the study.
From: Omentin-1 is associated with atrial fibrillation in patients with cardiac valve disease
|  | AF (n = 24) | nAF (n = 24) | P value |
|---|---|---|---|
Gender (m/f) | 10/14 | 9/15 | 0.768 |
Age (years) | 55.33 ± 7.88 | 54.58 ± 11.53 | 0.794 |
BMI | 23.25 ± 2.82 | 23.48 ± 3.42 | 0.806 |
NYHA class (n, I/II/III/IV) | 0/3/20/1 | 0/3/18/3 | 0.541 |
White cell (*10^9/L) | 5.66 ± 1.77 | 5.99 ± 1.51 | 0.492 |
Neutrophil (*10^9/L) | 3.51 ± 1.39 | 3.75 ± 1.14 | 0.521 |
Lymphocyte (*10^9/L) | 1.44 ± 0.58 | 1.53 ± 0.55 | 0.611 |
Blood glucose (mmol/l) | 6.01 ± 1.46 | 5.88 ± 1.98 | 0.799 |
TG (mmol/l) | 1.55 ± 0.74 | 1.83 ± 1.91 | 0.542 |
TC (mmol/l) | 3.90 ± 0.97 | 4.45 ± 1.26 | 0.115 |
HDL (mmol/l) | 0.90 ± 0.16 | 1.07 ± 0.26 | 0.013 |
LDL (mmol/l) | 2.49 ± 0.73 | 2.72 ± 0.76 | 0.319 |
CRP (mg/l) | 11.04 ± 19.61 | 17.86 ± 38.43 | 0.442 |
ESR (mm/h) | 34.61 ± 27.69 | 27.73 ± 26.11 | 0.396 |
NTproBNP (pg/ml) | 4118.52 ± 5309.2 | 3061.83 ± 2997.09 | 0.408 |
EF (%) | 52.17 ± 11.42 | 54.75 ± 9.06 | 0.599 |
RVD (mm) | 15.92 ± 4.62 | 16.63 ± 2.80 | 0.524 |
LVD (mm) | 47.96 ± 10.39 | 48.21 ± 8.93 | 0.929 |
LAD (mm) | 48.88 ± 8.34 | 38.50 ± 8.70 | 0.004 |
RAD (mm) | 48.50 ± 9.82 | 43.00 ± 8.48 | 0.043 |
Smoking (n, %) | 7 (29.17%) | 5 (20.83%) | 0.505 |
Drinking (n, %) | 2 (8.33%) | 4 (16.67%) | 0.383 |
Hypertension (n, %) | 5 (20.83%) | 5 (20.83%) | 1 |
CHD (n, %) | 7 (29.17%) | 3 (12.5%) | 0.155 |
Diabetes (n, %) | 3 (12.5%) | 0 (0%) | 0.074 |
Digitalis (n, %) | 20 (83.33%) | 15 (62.5%) | 0.104 |
Amiodarone (n, %) | 3 (12.5%) | 0 (0%) | 0.074 |
ACEI (n, %) | 2 (8.33%) | 2 (8.33%) | 1 |
ARB (n, %) | 1 (4.16%) | 1 (4.16%) | 1 |
β-blocker (n, %) | 12 (50%) | 17 (70.83%) | 0.140 |
Ca2+ antagonist (n, %) | 12 (50%) | 9 (37.5%) | 0.383 |
Statin (n, %) | 3 (12.5%) | 3 (12.5%) | 1 |